Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc develops gene therapies for age-related diseases, with company news centered on its SIRT6-based longevity platform and related therapeutic programs. Updates include progress in canine gene therapy work, intellectual property publications for SIRT6 applications, technology collaborations supporting delivery and genomic analysis, and engagement with animal health and biotechnology partners.
Genflow's announcements also cover operating and financial results, warrant exercises and equity issuance, total voting rights, and shareholder approvals for capital authorities. The company trades in London under GENF and on OTCQB under GENFF, and its public updates frequently use UK regulatory news channels for market disclosures.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) received notices to exercise warrants for 30,756,577 new ordinary shares, generating gross proceeds of £359,374.99. The issuance comprises 2,631,578 shares at 1.9p and 28,124,999 shares at an adjusted price of 1.1p.
Admission of the Warrant Shares to the FCA Official List and LSE main market is expected on or around 13 May 2026, raising the total issued share capital and voting rights to 566,409,782 shares.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) released final results for the year ended 31 December 2025 and will publish its Annual Report and AGM notice shortly. Key program milestones include a completed dog aging proof-of-concept dosing phase with no adverse events and advancement of MASH (GF-1002) toward clinical readiness with GMP production success and a €4m Wallonia grant reaffirmed.
IP expansion, new commercial CDAs, a pre-IND MSA, and an AI partnership were also disclosed.
Genflow Biosciences (LSE:GENF; OTCQB:GENFF) announced an expansion of confidentiality agreements with additional Tier‑1 global animal health companies on April 28, 2026. The agreements extend third‑party review of data from its canine SIRT6 cent gene therapy programme following positive preliminary interim results reported February 12, 2026.
The interactions are exploratory and the company said it will provide further updates as appropriate.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced a strategic technology collaboration with Acuitas Therapeutics on April 20, 2026. The fully funded, non-dilutive agreement gives Genflow access to Acuitas' lipid nanoparticle (LNP) delivery platform to test its SIRT6 mRNA payload in preclinical studies.
The collaboration covers formulation of Genflow's SIRT6 mRNA by Acuitas, return of LNP formulations for Genflow's preclinical evaluation, and establishes a framework for possible further development subject to preclinical outcomes. The company does not expect near-term revenue impact.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced the international publication of its PCT application WO 2026/062177 A1, covering SIRT6 variants for prevention and treatment of muscular diseases including frailty syndrome and sarcopenia.
The publication broadens Genflow's SIRT6 IP scope internationally, preserves multi-jurisdictional patent filing options, and supports potential development and partnering of its gene therapy platform.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced its total issued share capital and voting rights as of 31 March 2026. The company has 535,653,205 ordinary shares of £0.0003 each, with none held in treasury, so total voting rights equal 535,653,205.
Shareholders may use this figure as the denominator for FCA Disclosure Guidance and Transparency Rules notifications regarding changes in shareholding.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) raised £800,000 by issuing 42,105,263 new ordinary shares at 1.9p each, with one warrant per subscription share exercisable at the same price for two years. Admission of the new shares is expected around 11 March 2026.
The net proceeds are intended to fund scientific programs, extend cash runway and support potential licensing negotiations; CEO Eric Leire and chairman Gad Berdugo participated in the Subscription.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced that all resolutions at its General Meeting on March 2, 2026 were duly passed by shareholders. Proxy voting showed strong support for both the directors' authority to allot securities and the disapplication of pre-emption rights.
The company reported vote totals and percentages for each resolution, with over 97% of votes cast in favour on both items and detailed proxy counts provided.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) confirmed receipt of the first instalment of a €4.0 million non-dilutive grant from the Wallonia Region.
The company received €336,467 on March 2, 2026, for a three-year development programme supporting GF-1002 in MASH, with further instalments tied to milestone-based disbursements and applied to eligible project activities.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) reports positive preliminary interim results from the SLAB trial testing its SIRT6 gene therapy in aged beagles. The randomised, blinded study enrolled 24 dogs aged >10 years across four groups. During the dosing period, all treated cohorts showed superior survival, functional gains and a favourable safety profile versus control. Key mechanistic endpoints—methylation clock and muscle histology—remain under analysis, with a comprehensive update expected within approximately two months.